Comparison of bone marrow‑vs. adipose tissue‑derived mesenchymal stem cells for attenuating liver fibrosis

Hao,Tianpao; Chen,Jingfeng; Zhi,Shaoce; Zhang,Qiyu; Chen,Gang; Yu,Fuxiang

doi:10.3892/etm.2017.5333

Comparison of bone marrow‑vs. adipose tissue‑derived mesenchymal stem cells for attenuating liver fibrosis

Authors:
- Tianpao Hao
- Jingfeng Chen
- Shaoce Zhi
- Qiyu Zhang
- Gang Chen
- Fuxiang Yu
View Affiliations

Affiliations: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, Department of Anorectal Surgery, The Sixth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang 325000, P.R. China
Published online on: October 18, 2017 https://doi.org/10.3892/etm.2017.5333
Pages: 5956-5964
Copyright: © Hao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mesenchymal stem cell (MSC) therapy has emerged as a potential novel method of treating liver fibrosis. To date, bone marrow‑derived MSCs (BM‑MSCs) and adipose tissue‑derived MSCs (AD‑MSCs) have not been analyzed with respect to their ability to combat liver fibrosis. The present study aimed to compare the capabilities of BM‑MSCs and AD‑MSCs in the treatment of liver fibrosis. BM‑MSCs and AD‑MSCs were taken from male Sprague‑Dawley rats and cultured. Hepatic stellate cells (HSCs) were co‑cultured with either BM‑MSCs or AD‑MSCs, and the effects of BM‑MSCs or AD‑MSCs on the proliferation, activation and apoptosis of HSCs were determined. The secretion of a selected group of cytokines by BM‑MSCs and AD‑MSCs was measured using enzyme‑linked immunosorbent assays. Using a CCl4‑induced liver fibrosis animal model, the anti‑inflammatory and anti‑fibrotic effects of BM‑MSCs or AD‑MSCs against liver fibrosis in vivo were evaluated. The morphological examination and analysis of specific surface markers confirmed the successful preparation of BM‑MSCs and AD‑MSCs. Furthermore, the proliferation, activation and apoptosis of HSCs were significantly inhibited by BM‑MSCs and AD‑MSCs, with statistically greater reductions achieved by AD‑MSCs compared with BM‑MSCs. Direct comparison of the secretion of selected cytokines by BM‑MSCs and AD‑MSCs revealed that significantly higher levels of nerve growth factor and transforming growth factor‑β1 were secreted in the AD‑MSC culture medium, whereas levels of vascular endothelial growth factor and interleukin‑10 did not differ significantly between AD‑MSCs and BM‑MSCs. In vivo studies using a CCl4‑induced liver fibrosis model demonstrated that inflammatory activity and fibrosis staging scores were significantly lower in the MSC‑treated groups compared with controls. Although AD‑MSCs improved anti‑inflammatory and anti‑fibrotic effects compared with BM‑MSCs, these differences were not significant. Thus, the current study demonstrated that BM‑MSCs and AD‑MSCs are similarly effective at attenuating liver fibrosis by inhibiting the activation and proliferation of HSCs, as well as promoting the apoptosis of HSCs.

View Figures

View References

1	Friedman SL: Liver fibrosis-from bench to bedside. J Hepatol. 38 Suppl 1:S38–S53. 2003. View Article : Google Scholar : PubMed/NCBI
2	Bosch J and García-Pagán JC: Complications of cirrhosis. I. Portal hypertension. J Hepatol. 32 1 Suppl:S141–S156. 2000. View Article : Google Scholar
3	Cárdenas A: Hepatorenal syndrome: A dreaded complication of end-stage liver disease. Am J Gastroenterol. 100:460–467. 2005. View Article : Google Scholar : PubMed/NCBI
4	Bataller R and Brenner DA: Liver fibrosis. J Clin Invest. 115:209–218. 2005. View Article : Google Scholar : PubMed/NCBI
5	Friedman SL: Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 88:125–172. 2008. View Article : Google Scholar : PubMed/NCBI
6	Salem HK and Thiemermann C: Mesenchymal stromal cells: Current understanding and clinical status. Stem Cells. 28:585–596. 2010.PubMed/NCBI
7	Dezawa M, Ishikawa H, Itokazu Y, Yoshihara T, Hoshino M, Takeda S, Ide C and Nabeshima Y: Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science. 309:314–317. 2005. View Article : Google Scholar : PubMed/NCBI
8	Das M, Sundell IB and Koka PS: Adult mesenchymal stem cells and their potency in the cell-based therapy. J Stem Cells. 8:1–16. 2013.PubMed/NCBI
9	Lu T, Yang C, Sun H, Lv J, Zhang F and Dong XJ: FGF4 and HGF promote differentiation of mouse bone marrow mesenchymal stem cells into hepatocytes via the MAPK pathway. Genet Mol Res. 13:415–424. 2014. View Article : Google Scholar : PubMed/NCBI
10	Ren G, Chen X, Dong F, Li W, Ren X, Zhang Y and Shi Y: Concise review: Mesenchymal stem cells and translational medicine: Emerging issues. Stem Cells Transl Med. 1:51–58. 2012. View Article : Google Scholar : PubMed/NCBI
11	Sakaida I, Terai S, Yamamoto N, Aoyama K, Ishikawa T, Nishina H and Okita K: Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology. 40:1304–1311. 2004. View Article : Google Scholar : PubMed/NCBI
12	Chamberlain G, Fox J, Ashton B and Middleton J: Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 25:2739–2749. 2007. View Article : Google Scholar : PubMed/NCBI
13	Qi Z, Zhang Y, Liu L, Guo X, Qin J and Cui G: Mesenchymal stem cells derived from different origins have unique sensitivities to different chemotherapeutic agents. Cell Biol Int. 36:857–862. 2012. View Article : Google Scholar : PubMed/NCBI
14	Berardis S, Lombard C, Evraerts J, El Taghdouini A, Rosseels V, Sancho-Bru P, Lozano JJ, van Grunsven L, Sokal E and Najimi M: Gene expression profiling and secretome analysis differentiate adult-derived human liver stem/progenitor cells and human hepatic stellate cells. PLoS One. 9:e861372014. View Article : Google Scholar : PubMed/NCBI
15	Takeda M, Yamamoto M, Isoda K, Higashiyama S, Hirose M, Ohgushi H, Kawase M and Yagi K: Availability of bone marrow stromal cells in three-dimensional coculture with hepatocytes and transplantation into liver-damaged mice. J Biosci Bioeng. 100:77–81. 2005. View Article : Google Scholar : PubMed/NCBI
16	Yu F, Ji S, Su L, Wan L, Zhang S, Dai C, Wang Y, Fu J and Zhang Q: Adipose-derived mesenchymal stem cells inhibit activation of hepatic stellate cells in vitro and ameliorate rat liver fibrosis in vivo. J Formos Med Assoc. 114:130–138. 2015. View Article : Google Scholar : PubMed/NCBI
17	Liu Y, Wang Z, Wang J, Lam W, Kwong S, Li F, Friedman SL, Zhou S, Ren Q, Xu Z, et al: A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling. Liver Int. 33:504–515. 2013. View Article : Google Scholar : PubMed/NCBI
18	Majumder S, Piguet AC, Dufour JF and Chatterjee S: Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. Eur J Pharmacol. 705:86–95. 2013. View Article : Google Scholar : PubMed/NCBI
19	Chen YX, Huang YH, Zheng WD, Chen ZX, Zhang LJ and Wang XZ: Interleukin-10 gene modification attenuates hepatocyte activation of rat hepatic stellate cells in vitro. Mol Med Rep. 7:371–378. 2013. View Article : Google Scholar : PubMed/NCBI
20	Yu F, Su L, Ji S, Zhang S, Yu P, Zheng Y and Zhang Q: Inhibition of hepatic stellate cell activation and liver fibrosis by fat-specific protein 27. Mol Cell Biochem. 369:35–43. 2012. View Article : Google Scholar : PubMed/NCBI
21	Sumida Y, Nakajima A and Itoh Y: Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 20:475–485. 2014. View Article : Google Scholar : PubMed/NCBI
22	Yu J, Zhang S, Chu ES, Go MY, Lau RH, Zhao J, Wu CW, Tong L, Zhao J, vPoon TC and Sung JJ: Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro. Int J Biochem Cell Biol. 42:948–957. 2010. View Article : Google Scholar : PubMed/NCBI
23	Liu Y, Wang Z, Wang J, Lam W, Kwong S, Li F, Friedman SL, Zhou S, Ren Q, Xu Z, et al: A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signaling. Liver Int. 33:504–515. 2013. View Article : Google Scholar : PubMed/NCBI
24	Huang X, Wang X, Lv Y, Xu L, Lin J and Diao Y: Protection effect of kallistatin on carbon tetrachloride-induced liver fibrosis in rats via antioxidative stress. PLoS One. 9:e884982014. View Article : Google Scholar : PubMed/NCBI
25	Sato Y, Araki H, Kato J, Nakamura K, Kawano Y, Kobune M, Sato T, Miyanishi K, Takayama T, Takahashi M, et al: Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood. 106:756–763. 2005. View Article : Google Scholar : PubMed/NCBI
26	Sharma RR, Pollock K, Hubel A and McKenna D: Mesenchymal stem or stromal cells: A review of clinical applications and manufacturing practices. Transfusion. 54:1418–1437. 2014. View Article : Google Scholar : PubMed/NCBI
27	Wang J, Bian C, Liao L, Zhu Y, Li J, Zeng L and Zhao RC: Inhibition of hepatic stellate cells proliferation by mesenchymal stem cells and the possible mechanisms. Hepatol Res. 39:1219–1228. 2009. View Article : Google Scholar : PubMed/NCBI
28	Haddad R and Saldanha-Araujo F: Mechanisms of T-cell immunosuppression by mesenchymal stromal cells: What do we know so far? Biomed Res Int. 2014:2168062014. View Article : Google Scholar : PubMed/NCBI
29	Sakaida I, Terai S, Yamamoto N, Aoyama K, Ishikawa T, Nishina H and Okita K: Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology. 40:1304–1311. 2004. View Article : Google Scholar : PubMed/NCBI
30	Ma ZG, Lv XD, Zhan LL, Chen L, Zou QY, Xiang JQ, Qin JL, Zhang WW, Zeng ZJ, Jin H, et al: Human urokinase-type plasminogen activator gene-modified bone marrow-derived mesenchymalstem cells attenuate liver fibrosis in rats by down-regulating the Wnt signaling pathway. World J Gastroenterol. 22:2092–2103. 2016. View Article : Google Scholar : PubMed/NCBI
31	Iyer SS and Cheng G: Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 32:23–63. 2012. View Article : Google Scholar : PubMed/NCBI
32	Liedtke C, Luedde T, Sauerbruch T, Scholten D, Streetz K, Tacke F, Tolba R, Trautwein C, Trebicka J and Weiskirchen R: Experimental liver fibrosis research: Update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair. 6:192013. View Article : Google Scholar : PubMed/NCBI